tradingkey.logo

Stereotaxis Inc

STXS

2.800USD

+0.040+1.45%
Close 09/18, 16:00ETQuotes delayed by 15 min
240.80MMarket Cap
LossP/E TTM

Stereotaxis Inc

2.800

+0.040+1.45%
More Details of Stereotaxis Inc Company
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Company Info
Ticker SymbolSTXS
Company nameStereotaxis Inc
IPO dateAug 12, 2004
CEOMr. David Leo Fischel
Number of employees139
Security typeOrdinary Share
Fiscal year-endAug 12
Address710 N Tucker Blvd
CityST. LOUIS
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code63101
Phone13146786100
Websitehttps://www.stereotaxis.com/
Ticker SymbolSTXS
IPO dateAug 12, 2004
CEOMr. David Leo Fischel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Nathan Fischel, M.D.
Dr. Nathan Fischel, M.D.
Director
Director
13.92M
+0.31%
Mr. David W. Benfer
Mr. David W. Benfer
Lead Independent Director
Lead Independent Director
506.97K
+9.43%
Dr. Myriam J. Curet, M.D.
Dr. Myriam J. Curet, M.D.
Independent Director
Independent Director
345.11K
+14.49%
Mr. David Leo Fischel
Mr. David Leo Fischel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
200.00K
+42.86%
Mr. Ross B. Levin
Mr. Ross B. Levin
Independent Director
Independent Director
138.64K
+45.98%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Director
Director
89.28K
+95.75%
Dr. Arun Swarup Menawat, Ph.D.
Dr. Arun Swarup Menawat, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberly R. Peery
Ms. Kimberly R. Peery
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Nathan Fischel, M.D.
Dr. Nathan Fischel, M.D.
Director
Director
13.92M
+0.31%
Mr. David W. Benfer
Mr. David W. Benfer
Lead Independent Director
Lead Independent Director
506.97K
+9.43%
Dr. Myriam J. Curet, M.D.
Dr. Myriam J. Curet, M.D.
Independent Director
Independent Director
345.11K
+14.49%
Mr. David Leo Fischel
Mr. David Leo Fischel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
200.00K
+42.86%
Mr. Ross B. Levin
Mr. Ross B. Levin
Independent Director
Independent Director
138.64K
+45.98%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Director
Director
89.28K
+95.75%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
International
13.49M
50.12%
United States
13.43M
49.88%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Aug 13
Updated: Wed, Aug 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fischel (Nathan)
15.28%
Dafna Capital Management, LLC
15.02%
Kiani (Joe E)
9.73%
Lagoda Investment Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
3.96%
Other
50.86%
Shareholders
Shareholders
Proportion
Fischel (Nathan)
15.28%
Dafna Capital Management, LLC
15.02%
Kiani (Joe E)
9.73%
Lagoda Investment Management, L.P.
5.15%
BlackRock Institutional Trust Company, N.A.
3.96%
Other
50.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
29.25%
Hedge Fund
19.28%
Investment Advisor
17.15%
Investment Advisor/Hedge Fund
9.29%
Corporation
3.38%
Research Firm
0.44%
Bank and Trust
0.06%
Insurance Company
0.02%
Pension Fund
0.01%
Other
21.12%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
184
70.71M
77.86%
+13.38M
2025Q1
192
70.55M
82.04%
+9.72M
2024Q4
185
55.40M
64.94%
-4.27M
2024Q3
178
54.77M
64.71%
-4.91M
2024Q2
173
55.07M
66.24%
-4.36M
2024Q1
185
55.40M
67.15%
-4.49M
2023Q4
184
51.49M
64.77%
-9.27M
2023Q3
189
52.12M
65.60%
-9.17M
2023Q2
205
51.88M
65.54%
-5.57M
2023Q1
209
48.14M
64.14%
-13.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fischel (Nathan)
13.88M
16.14%
+13.63M
+5575.52%
Mar 17, 2025
Dafna Capital Management, LLC
13.68M
15.91%
--
--
Mar 31, 2025
Kiani (Joe E)
8.86M
10.3%
+427.40K
+5.07%
Mar 17, 2025
Lagoda Investment Management, L.P.
4.38M
5.09%
+254.31K
+6.16%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.54M
4.11%
-109.40K
-3.00%
Mar 31, 2025
The Vanguard Group, Inc.
3.53M
4.11%
+58.52K
+1.68%
Mar 31, 2025
2012 Revocable Trust of Andrew Redleaf
3.08M
3.58%
--
--
Mar 17, 2025
Arbiter Partners Capital Management, LLC
2.85M
3.32%
+62.79K
+2.25%
Mar 31, 2025
Isaac (Paul J)
2.05M
2.39%
+2.05M
--
Mar 10, 2025
Essex Investment Management Company, LLC
1.56M
1.81%
+343.13K
+28.29%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI